Enhancement of Secretory Aspartyl Protease production in biofilms of Candida albicans exposed to sub-inhibitory concentrations of fluconazole

Mycoses

Volumn 54, Issue 3, 2011, Pages 195-201

  Mores, Alinne Ulbrich ^a   Souza, Roberta Djavana ^a   Cavalca, Laura ^a   de Paula e Carvalho, Alessandra ^a   Gursky, Lauren Christine ^a,b   Rosa, Rosimeire Takaki ^a   Samaranayake, Lakshman Perera ^c   Rosa, Edvaldo Antonio Ribeiro ^a,c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FORSYTH INSTITUTE   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aspartyl protease; Biofilm; Candida albicans; Fluconazole

Indexed keywords

ASPARTIC PROTEINASE; FLUCONAZOLE; FUNGAL ENZYME; SECRETORY ASPARTYL PROTEASE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL CELL; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME RELEASE; ENZYME SYNTHESIS; FUNGAL CELL; FUNGAL METABOLISM; FUNGUS CULTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLANKTONIC CELL; PRIORITY JOURNAL; SUB INHIBITORY CONCENTRATION;

ANTIFUNGAL AGENTS; ASPARTIC ACID PROTEASES; BIOFILMS; CANDIDA ALBICANS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECTROPHOTOMETRY; TETRAZOLIUM SALTS; VIRULENCE FACTORS;

BOVINAE; CANDIDA; CANDIDA ALBICANS;

EID: 79954452648     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01793.x     Document Type: Article

References (40)

1. McCullough MJ, Ross BC, Reade PC. Candida albicans: a review of its history, taxonomy, virulence attributes, and methods of strain differentiation. Int J Oral Maxillofac Surg 1996; 25: 136-44.
2. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 2000; 13: 122-43.
3. Oliveira EE, Silva SC, Soares AJ, Attux C, Cruvinel B, Silva MR. Killer toxin and enzyme production by Candida albicans isolated from buccal mucosa in patients with cancer. Rev Soc Bras Med Trop 1998; 31: 523-7.
4. Abu-Elteen KH, Elkarmi AZ, Hamad M. Characterization of phenotype-based pathogenic determinants of various Candida albicans strains in Jordan. Jpn J Infect Dis 2001; 54: 229-36.
5. Shimizu MT, Almeida NQ, Fantinato V, Unterkircher CS. Studies on hyaluronidase; chondroitin sulphatase; proteinase and phospholipase secreted by Candida species. Mycoses 1996; 39: 161-7.
6. De Bernardis F, Mondello F, San Millàn R, Pontòn J, Cassone A. Biotyping and virulence properties of skin isolates of Candida parapsilosis. J Clin Microbiol 1999; 37: 3481-6.
7. Ueta E, Tanida T, Yoneda K, Yamamoto T, Osaki T. Increase of Candida cell virulence by anticancer drugs and irradiation. Oral Microbiol Immunol 2001; 16: 243-9.
8. Willis AM, Coulter WA, Fulton CR, Hayes JR, Bell PM, Lamey PJ. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91: 317-21.
9. Fekete-Forgacs K, Gyure L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses 2000; 43: 273-9.
10. Borg-von Zepelin M, Niederhaus T, Gross U, Seibold M, Monod M, Tintelnot K. Adherence of different Candida dubliniensis isolates in the presence of fluconazole. AIDS 2002; 16: 1237-44.
11. Navarathna DH, Hornby JM, Hoerrmann N, Parkhurst AM, Duhamel GE, Nickerson KW. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis. J Antimicrob Chemother 2005; 56: 1156-9.
12. Anil S, Samaranayake LP. Brief exposure to antimycotics reduces the extracellular phospholipase activity of Candida albicans and Candida tropicalis. Chemotherapy 2003; 49: 243-7.
13. Graybill JR, Montalbo E, Kirkpatrick WR, Luther MF, Revankar SG, Patterson TF. Fluconazole versus Candida albicans: a complex relationship. Antimicrob Agents Chemother 1998; 42: 2938-42.
14. Hazen KC, Mandell G, Coleman E, Wu G. Influence of fluconazole at subinhibitory concentrations on cell surface hydrophobicity and phagocytosis of Candida albicans. FEMS Microbiol Lett 2000; 183: 89-94.
15. Kontoyiannis DP, Tarrand J, Prince R, Samonis G, Rolston KV. Effect of fluconazole on agar invasion by Candida albicans. J Med Microbiol 2001; 50: 78-82.
16. Mendes A, Mores AU, Carvalho AP, Rosa RT, Samaranayake LP, Rosa EAR. Candida albicans biofilms produce more Secreted Aspartyl Protease than the planktonic cells. Biol Pharm Bull 2007; 30: 1813-5.
17. Thiele MC, Carvalho Ade P, Gursky LC, Rosa RT, Samaranayake LP, Rosa EA. The role of candidal histolytic enzymes on denture-induced stomatitis in patients living in retirement homes. Gerodontology 2008; 25: 229-36.
18. Chandra J, Mukherjee PK, Leidich SD et al. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 2001; 80: 903-8.
19. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of yeasts - Document M27-A2. 2nd edn. Pennsylvania: NCCLS, 2002.
20. Koga-Ito CY, Paiva-Martins CA, Loberto JC, Santos SS, Jorge AOC. In vitro antifungal susceptibility of Candida spp. isolates from patients with chronic periodontitis and from control patients. Braz Oral Res 2004; 18: 80-4.
21. Bellamine A, Lepesheva GI, Waterman MR. Fluconazole binding and sterol demethylation in three CYP51 isoforms indicate differences in active site topology. J Lipid Res 2004; 45: 2000-7.
22. Silva WJ, Seneviratne J, Parahitiyawa N, Rosa EA, Samaranayake LP, Del Bel Cury AA. Improvement of XTT assay performance for studies involving Candida albicans biofilms. Braz Dent J 2008; 19: 364-9.
23. De Bernardis F, Mondello F, Scaravelli G et al. High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women. J Clin Microbiol 1999; 37: 1376-80.
24. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of Yeasts: approved standard, 3rd edn. M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
25. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003; 47: 1805-17.
26. Schaller M, Krnjaic N, Niewerth M, Hamm G, Hube B, Korting HC. Effect of antimycotic agents on the activity of aspartyl proteinases secreted by Candida albicans. J Med Microbiol 2003; 52: 247-9.
27. Copping VMS, Barelle CJ, Hube B, Gow NAR, Brown AJP, Odds FC. Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimicrob Chemother 2005; 55: 645-54.
28. Imbert C, Imbert-Bouyer S, Kauffmann-Lacroix C, Daniault G, Rodier MH. Effect of azoles on the secretion of a Candida albicans metallopeptidase. Mycopathologia 2006; 161: 147-52.
29. Ozkan S, Kaynak F, Kalkanci A, Abbasoglu U, Kustimur S. Slime production and proteinase activity of Candida species isolated from blood samples and the comparison of these activities with minimum inhibitory concentration values of antifungal agents. Mem Inst Oswaldo Cruz 2005; 100: 319-24.
30. Wu T, Wright K, Hurst SF, Morrison CJ. Enhanced extracellular production of aspartyl proteinase; a virulence factor; by Candida albicans isolates following growth in subinhibitory concentrations of fluconazole. Antimicrob Agents Chemother 2000; 44: 1200-8.
31. Barelle CJ, Duncan VM, Brown AJ, Gow NA, Odds FC. Azole antifungals induce up-regulation of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo. J Antimicrob Chemother 2008; 61: 315-22.
32. Ramage G, Saville SP, Thomas DP, López-Ribot JL. Candida biofilms: an update. Eukaryot Cell 2005; 4: 633-8.
33. Perumal P, Mekala S, Chaffin WL. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob Agents Chemother 2007; 51: 2454-63.
34. Samaranayake YH, Ye J, Yau JY, Cheung BP, Samaranayake LP. In vitro method to study antifungal perfusion in Candida biofilms. J Clin Microbiol 2005; 43: 818-25.
35. Bruzual I, Riggle P, Hadley S, Kumamoto CA. Biofilm formation by fluconazole-resistant Candida albicans strains is inhibited by fluconazole. J Antimicrob Chemother 2007; 59: 441-50.
36. Hornby JM, Nickerson KW. Enhanced production of farnesol by Candida albicans treated with four azoles. Antimicrob Agents Chemother 2004; 48: 2305-7.
37. Hornby JM, Kebaara BW, Nickerson KW. Farnesol biosynthesis in Candida albicans: cellular response to sterol inhibition by zaragozic acid B. Antimicrob Agents Chemother 2003; 47: 2366-9.
38. Hornby JM, Jensen EC, Lisec AD et al. Quorum sensing in the dimorphic fungus Candida albicans is mediated by farnesol. Appl Environ Microbiol 2001; 67: 2982-92.
39. Ramage G, Saville SP, Wickes BL, López-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 2002; 68: 5459-63.
40. Dubois N, Colina AR, Aumont F, Belhumeur P, Repentigny L. Overexpression of Candida albicans secretory aspartyl proteinase 2 and its expression in Saccharomyces cerevisiae do not augment virulence in mice. Microbiology 1998; 144: 2299-310.